Enveric Biosciences Reports Q3 2026 GAAP EPS of -$0.57
Enveric Biosciences (ENVB) has announced its financial results for the third quarter ended September 30, 2026. The company reported a basic and diluted loss per share of $0.57, reflecting a net loss attributable to stockholders of $2.5 million during the period. The reported figures include $0.2 million in net non-cash expenses. These results highlight the ongoing operational costs as the company continues its clinical or research activities within the biotechnology sector.
Tickers: $ENVB
Topics: earnings report GAAP EPS net loss